**UF BPA Appendix for the August 2015 DoD P&T Meeting**

Uniform Formulary Price Quotes and

Uniform Formulary Blanket Purchase Agreements (BPA)

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF BPA price quotes are to be submitted by the Company.

Medications placed on the Uniform Formulary but not BCF or ECF are available for the local Military Treatment Facility P&T to decide whether to place on their individual formulary.

The Company must submit a separate, complete UF BPA price quote for each NDC (enter in table below\*) that applies to the Company’s pharmaceutical agent(s) in a given drug class.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NDC** | **Drug Name** | **Strength** | **Dosage Form** | **Package Size** |
|  |  |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DoD P&T Class: DIABETES NON-INSULIN**  **DoD P&T Sub-Class: SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS** | | | | |
| **Class Note(s):** Step therapy – Must try at least 3 different diabetes drug classes before using a SGLT2 inhibitor (Group 1) AND (Group 2) AND (Group 3) – one group must be metformin. Existing fixed-dose combinations will follow the parent compound (e.g. branded SGLT2 combined with metformin will have same branded SGLT2 UF status). PC = Parent Compound; FDC = Fixed Dose Combinations. | | | | |
| **Step Therapy Addendum: *No grandfathering:*** a prior authorization process, would require all patients, regardless of past medication history to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user. | | | | |
| **Condition Set #** | **Category \*** | **One of (X) number of brand agents** | **Military Treatment Facility &**  **Mail Order** | |
| **Price per Unit of Measure (each, gram, mL) to 4 decimal places** | **Price Per NDC to**  **2 decimal places** |
| **Military Treatment Facility & Mail**  **154DNGLN1UFBS1X** | **Uniform Formulary but not BCF or ECF Before Step Therapy** | **1**  **(FDC+PC)** | **$** | **$** |
|  |  |  |  | |
| **Military Treatment Facility & Mail**  **154DNGLN0UFNS1M** | **Uniform Formulary but not BCF or ECF No Step Therapy** | **1 or more**  **(FDC+PC)** | **$** | **$** |
|  |  |  |  | |

**\* Only one price per category may be submitted.**

**UF VARR Appendix for the August 2015 DoD P&T Meeting**

**Condition Sets for Uniform Formulary Voluntary Agreements for TRICARE Retail Refunds (UF-VARR)**

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF-VARR quotes are to be submitted by the Company.

The Company must submit a separate, complete UF-VARR quote for each Condition Set that applies to the Company’s pharmaceutical agents in a given drug class. The Company must record the Condition Set # that applies to a given UF-VARR quote in the appropriate blank on Table 1, Uniform Formulary Refund Quote.

The refund quoted will apply to the resulting UF-VARR if the quoted pharmaceutical agent is selected for inclusion on the UF in no worse than the formulary (Tier 2) cost share. The refund quoted is not contingent on the quoted pharmaceutical agent being selected for inclusion on the BCF or ECF.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NDC** | **Drug Name** | **Strength** | **Dosage Form** | **Package Size** |
|  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **DoD P&T Class: DIABETES NON-INSULIN**  **DoD P&T Sub-Class: SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS** | | | | | | | | | | | | | |
| **Class Note(s):** Step therapy – Must try at least 3 different diabetes drug classes before using a SGLT2 inhibitor (Group 1) AND (Group 2) AND (Group 3) – one group must be metformin. Existing fixed-dose combinations will follow the parent compound (e.g. branded SGLT2 combined with metformin will have same branded SGLT2 UF status). PC = Parent Compound; FDC = Fixed Dose Combinations. | | | | | | | | | | | | | |
| **Step Therapy Addendum: *No grandfathering:*** a prior authorization process, would require all patients, regardless of past medication history to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user. | | | | | | | | | | | | | |
| **Condition Set #** | | | | | | | **Category\*\*** | **One of (X) Number of brand agents** | **Most recent Annual Non-Federal Average Manufacturer's Price\* (NFAMP) per FCP Package Size.**  **CHANGES ANNUALLY**  **($)** | **Current Annual Federal Ceiling Price\* (FCP) per FCP Package Size.**  **CHANGES ANNUALLY**  **($)** | **Standard Refund per FCP Package Size**  **CHANGES ANNUALLY**  **((NFAMP – FCP )/NFAMP) \*100 = X%**  **(%)** | **Additional Refund per FCP Package Size**  **Percentage is Static**  **NFAMP \*(Y%)**  **(%)** | **Total Offered Retail Refund per FCP Package Size**  **CHANGES ANNUALLY**  **(((NFAMP – FCP )/NFAMP) \*100 = X%) + (NFAMP \*(Y%)) = Total%**  **(%)** |
| **154DNGLN1T2BS1X** | | | | | | | **Tier 2 & Before Step Therapy** | **1**  **(FDC+PC)** | $ | $ | % | % | % |
|  | | | | | | |  |  |  |  |  |  |  |
| **154DNGLN0T2NS1X** | | | | | | | **Tier 2 No Step Therapy** | **1 or more**  **(FDC+PC)** | $ | $ | % | % | % |
|  | | | | | | |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

**\*\* Only one price per category may be submitted.**